Nemolizumab is a medicine used to treat prurigo nodularis, a condition with very itchy bumps on the skin, and moderate to severe eczema. It is given as a shot under the skin. It works by blocking a signal in the body, called IL-31, that causes itching.
Every report comes from a Lived member, sent anonymously.
Have you tried Nemluvio (Nemolizumab) for Prurigo?
Nemolizumab, sold as Nemluvio, is a prescription injection for two long-lasting skin conditions in which itch is the main problem. It is approved for adults with prurigo nodularis, a chronic condition that causes firm, intensely itchy bumps (nodules) on the skin. It is also approved for adults and children 12 and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled by prescription creams and ointments. For eczema, nemolizumab is added to topical treatment rather than replacing it: people keep using a corticosteroid cream or a calcineurin inhibitor (a non-steroid anti-inflammatory cream or ointment) while starting the injections. For prurigo nodularis it can be used on its own. Its safety and benefit have not been established in children younger than 12 for eczema or in anyone under 18 for prurigo nodularis.
Interleukin-31 (IL-31) is a signaling protein made by immune cells in the skin. It acts on nerves to trigger itch and also feeds skin inflammation and thickening. Nemolizumab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. It blocks the receptor that IL-31 normally binds to, so the itch signal has less effect. Because itch drives scratching, and scratching in turn worsens nodules and eczema patches, quieting the itch can help break that cycle and give the skin a chance to heal.
Nemluvio comes as a single-use prefilled pen injected under the skin of the thigh or abdomen (a caregiver or clinician may also use the upper arm). Treatment starts with two injections on the first day, given at different sites, followed by one injection every 4 weeks. For prurigo nodularis, people weighing 90 kg (about 198 pounds) or more use a higher maintenance dose. For eczema, people whose skin is clear or almost clear after 16 weeks may be moved to an injection every 8 weeks. The pen has two chambers, a powder and a liquid, that must be mixed inside the pen before injecting. After taking it out of the refrigerator, it needs 30 to 45 minutes to reach room temperature, and once mixed it must be used within 4 hours. People can inject at home after a clinician has trained them; teenagers should inject with an adult's help or supervision. If a dose is missed, give it as soon as possible and then return to the usual schedule.
Most people tolerate nemolizumab well. In the trials, headache was the most common side effect. People with prurigo nodularis sometimes developed eczema-type rashes, including round, coin-shaped patches, while people treated for eczema occasionally had joint pain, muscle aches or hives. A small number of people in the eczema trials developed shingles, which was mild to moderate. Reactions at the injection site were uncommon. Allergic reactions can happen and are occasionally serious. Trouble breathing, wheezing, swelling of the face, lips, tongue or throat, or fainting after a dose needs emergency care right away. Milder signs such as a new rash, hives, fever or swollen glands should be reported to the prescriber promptly, and the next dose should wait until they have advised.
Nemolizumab should not be used by anyone who has had an allergic reaction to it or to its ingredients. Before starting, it is worth bringing vaccinations up to date, because live vaccines should be avoided during treatment. Let any clinician giving a vaccine know you are on nemolizumab. No specific medicine interactions are listed, but the prescriber should still know about everything else you take. There is too little information to know whether nemolizumab is safe in pregnancy or whether it passes into breast milk. Like other antibody medicines, it is expected to cross the placenta more in late pregnancy. Anyone who is pregnant, planning a pregnancy or breastfeeding should weigh this with their prescriber.
Itch is usually the first thing to change. In trial analyses, some people noticed less itch and better sleep within the first days to weeks, while visible healing of nodules or eczema patches tends to take longer. The trials judged results at 16 weeks. Not everyone responds. In the prurigo nodularis trials, about half of people taking nemolizumab had a large drop in itch at 16 weeks, compared with about one in six on placebo, and roughly a quarter to over a third had clear or almost clear skin. In the eczema trials, where everyone also used topical treatment, about 4 in 10 people had their eczema severity score fall by at least three quarters, compared with about 3 in 10 using topical treatment alone. Among people with eczema who responded, most kept that response through a year when they continued injections. Nemolizumab controls these conditions rather than curing them, so it is generally continued as long as it keeps working and is well tolerated. For eczema, the prescriber may reduce topical treatments once the skin has improved. Follow-up visits are used to judge whether the response is worth continuing and to adjust the plan.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Nemluvio (Nemolizumab), what you've noticed, or ask the community a question.